Preview

Российский неврологический журнал

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

ВОЗМОЖНОСТЬ ИСПОЛЬЗОВАНИЯ ГЛИАЛЬНОГО ФИБРИЛЛЯРНОГО КИСЛОГО БЕЛКА КАК БИОМАРКЕРА В ОСТРОМ ПЕРИОДЕ ИНСУЛЬТА

https://doi.org/10.30629/2658-7947-2019-24-4-4-15

Полный текст:

Аннотация

Высокая смертность и инвалидизация в результате перенесенного инсульта во всем мире являются причиной поиска новых возможностей для улучшения ранней диагностики и оптимизации терапевтических подходов. Представлен обзор литературы, посвященной изучению глиального фибриллярного кислого белка (ГФКБ) в качестве биомаркера в остром периоде инсульта и возможности его использования для дифференцирования ишемического и геморрагического процесса, а также в целях определения степени разрушения мозговой ткани, как в первые часы инсульта, так и в динамике. Кроме того анализ ГФКБ может быть полезен для мониторинга течения заболевания, контроля над эффективностью проводимой терапии, а также с целью прогнозирования исходов.

Об авторах

М. П. Топузова
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия

канд.мед.наук, доцент кафедры неврологии и психиатрии, старший научный сотрудник НИЛ цереброваскулярной патологии НИО неврологии и нейрореабилитации

197341, Санкт-Петербург, ул. Аккуратова, 2

 



Т. М. Алексеева
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2


Е. Б. Панина
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2


Т. В. Вавилова
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2


О. А. Портик
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2


П. Д. Ковзелев
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени B.A. Алмaзoвa» Минздрава России
Россия
197341, Санкт-Петербург, ул. Аккуратова, 2


Список литературы

1. Mukherjee D., Patil C.G. Epidemiology and the global burden of stroke. World Neurosurg. 2011 Dec;76(6 Suppl):S85–90. https://doi.org/10.1016/j.wneu.2011.07.023.

2. Bustamante A., López-Cancio E., Pich S., Penalba A., Giralt D., García-Berrocoso T., Ferrer-Costa C., Gasull T., et al. Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study. Stroke. 2017 Sep;48(9):2419–2425. https://doi.org/10.1161/STROKEAHA.117.01707.

3. Morgenstern L.B., Hemphill J.C. 3rd, Anderson C., Becker K., Broderick J.P., Connolly E.S. Jr, Greenberg S.M., Huang J.N., et al. American Heart Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010 Sep;41(9):2108–29. https://doi.org/10.1161/str.0b013e3181ec611b.

4. Connolly E.S. Jr., Rabinstein A.A., Carhuapoma J.R., Derdeyn C.P., Dion J., Higashida R.T., Hoh B.L., Kirkness C.J., et al.; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012 Jun;43(6):1711–37. https://doi.org/10.1161/STR.0b013e3182587839.

5. Adams H.P. Jr, del Zoppo G., Alberts M.J., Bhatt D.L., Brass L., Furlan A., Grubb R.L., Higashida R.T., et al.; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affi rms the value of this guideline as an educational tool for neurologists. Stroke. 2007 May;38(5):1655–711. https://doi.org/10.1161/STROKEAHA.107.181486.

6. Maas M.B., Furie K.L. Molecular biomarkers in stroke diagnosis and prognosis. Biomark Med. 2009 Aug 1;3(4):363–383. https://doi.org/10.2217/bmm.09.30.

7. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 Feb 6;115(5):e69–171. https://doi.org/10.1161/CIRCULATIONAHA.106.179918.

8. Whiteley W., Tseng M.C., Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008 Oct;39(10):2902–9. https://doi.org/10.1161/STROKEAHA.107.511261.

9. Castellanos M., Serena J. Applicability of biomarkers in ischemic stroke. Cerebrovasc. Dis. 2007;24 Suppl 1:7–15. https://doi.org/10.1159/000107374.

10. Saenger K.A., Christenson R.H. Stroke biomarkers: progress and challenges for diagnosis, prognosis, diff erentiation, and treatment. Clin. Chem. 2010; 56: 21–33. https://doi.org/10.1373/clinchem.2009.133801.

11. Brouns R., De Deyn P.P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg. 2009; 111:483–95. https://doi.org/10.1016/j.clineuro.2009.04.001.

12. Testai F.D., Aiyagari V. Acute hemorrhagic stroke pathophysiology and medical interventions: blood pressure control, management of anticoagulant-associated brain hemorrhage and general management principles. Neurol. Clin. 2008; 26: 963–85. https://doi.org/10.1016/j.ncl.2008.06.001.

13. Гусев Е.И. Проблема инсульта в России. Журнал неврологии и психиатрии им. C.C. Корсакова. 2003; 9: 3–7.

14. Lynch J.R., Blessing R., White W.D., Grocott H.P., Newman M.F., Laskowitz D.T. Novel diagnostic test for acute stroke. Stroke. 2004 Jan;35(1):57–63. https://doi.org/10.1161/01.STR.0000105927.62344.4C.

15. Worthmann H., Tryc A.B., Goldbecker A., Ma Y.T., Tountopoulou A., Hahn A., Dengler R., Lichtinghagen R., Weissenborn K. The temporal profi le of infl ammatory markers and mediators in blood after acute ischemic stroke diff ers depending on stroke outcome. Cerebrovasc. Dis. 2010;30(1):85–92. https://doi.org/10.1159/000314624.

16. Füst G., Munthe-Fog L., Illes Z., Széplaki G., Molnar T., Pusch G., Hirschberg K., Szegedi R., et al. Low fi colin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J. Neuroinfl ammation. 2011 Dec 29;8:185. https://doi.org/10.1186/1742-2094-8-185.

17. Doehner W., von Haehling S., Suhr J., et al. Elevated plasma levels of neuropeptide proenkephalin a predict mortality and functional outcome in ischemic stroke. J. Am. Coll. Cardiol. 2012; 60: 346–54. https://doi.org/10.1016/j.jacc.2012.04.024.

18. Eng L.F. Glial Fibrillary Acidic Protein (GFAP) the Major Protein of Glial Intermediate Filaments in Diff erentiated Astrocytes. Journal of Neuroimmunology. 1985;8:203-214. https://doi.org/10.1016/s0165–5728(85)80063–1.

19. Missler U., Wiesmann M., Wittmann G., Magerkurth O., Hagenström H. Measurement of glial fi brillary acidic protein in human blood: analytical method and preliminary clinical results. Clinical Chemistry. 1999;45:138–141.

20. Pelinka L.E., Kroepfl A., Leixnering M., Buchinger W., Raabe A., Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma. 2004 Nov;21(11):1553–61. https://doi.org/10.1089/neu.2004.21.1553.

21. Yang Z., Wang K.K. Glial fi brillary acidic protein: from intermediate fi lament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015 Jun;38(6):364–74. https://doi.org/10.1016/j.tins.2015.04.003.

22. Lundgaard I., Osório M.J., Kress B.T., Sanggaard S., Nedergaard M. White matter astrocytes in health and disease. Neuroscience. 2014 Sep 12;276:161–73. https://doi.org/10.1016/j.neuroscience.2013.10.050.

23. Lowenthal A., Noppe M., Gheuens J., Karcher D. Alpha albumin (glial fi brillary acidic protein) in normal and pathological human brain and cerebrospinal fl uid. Neuwl. 1978;219:87–91. https://doi.org/10.1007/bf00314391.

24. Wunderlich M.T., Wallesch C.W., Goertler M. Release of glial fi brillary acidic protein is related to the neurovascular status in acute ischemic stroke. Eur. J. Neurol. 2006; 13:1118–1123. https://doi.org/10.1111/j.1468–1331.2006.01435.x.

25. Nylén K., Csajbok L.Z., Ost M., Rashid A., Blennow K., Nellgård B., Rosengren L. Serum glial fi brillary acidic protein is related to focal brain injury and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2007; 38(5):1489–1494. https://doi.org/10.1161/STROKEAHA.106.478362.

26. Dvorak F., Haberer I., Sitzer M., Foerch C. Characterisation of the diagnostic window of serum glial fi brillary acidic protein for the diff erentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc. Dis. 2009;27(1):37–41. https://doi.org/10.1159/000172632.

27. Ehrenreich H., Kästner A., Weissenborn K., Streeter J., Sperling S., Wang K.K., Worthmann H., Hayes R.L., et al. Circulating damage marker profi les support a neuroprotective eff ect of erythropoietin in ischemic stroke patients. Mol. Med. 2011;17(11–12):1306–10. https://doi.org/10.2119/molmed.2011.00259.

28. Stanca D.M., Mărginean I.C., Sorițău O., Dragoș C., Mărginean M., Mureșanu D.F., Vester J.C., Rafi la A. GFAP and antibodies against NMDA receptor subunit NR2 as biomarkers for acute cerebrovascular diseases. J. Cell. Mol. Med. 2015 Sep;19(9):2253–61. https://doi.org/10.1111/jcmm.12614.

29. Vissers J.L., Mersch M.E., Rosmalen C.F., van Heumen M.J., van Geel W.J., Lamers K.J., Rosmalen F.M., Swinkels L.M., et al. Rapid immunoassay for the determination of glial fi brillary acidic protein (GFAP) in serum. Clin. Chim. Acta. 2006 Apr;366(1–2):336–40.https://doi.org/10.1016/j.cca.2005.11.017.

30. Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H.M.M., Lamers K.J.B. Release of glial tissue-specifi c proteins after acute stroke: acomparative analysis of serum concentrations of protein S-100B and glial fi brillary acidic protein. Stroke. 2000;31:2670–2677. https://doi.org/10.1161/01.str.31.11.2670.

31. Katsanos A.H., Makris K., Stefani D., Koniari K., Gialouri E., Lelekis M., Chondrogianni M., Zompola C., et al. Plasma glial fi brillary acidic protein in the diff erential diagnosis of intracerebral hemorrhage. Stroke. 2017;48(9):2586–2588. https://doi.org/10.1161/STROKEAHA.117.018409.

32. Kamchatnov P.R., Chugunov A.V., Ruleva N.Yu., Dugin S.F., Basse D.A., Abusueva B.A., Buriachkovskaya L.I., Gusev E.I. Autoantibodies to GFAP (glial fi brillary acidic protein) and to dopamine in patients with acute and chronic cerebrovascular disоrders. Health. 2010;2(12):1366–1371. https://doi.org/10.4236/health.2010.212202.

33. Ren C., Kobeissy F., Alawieh A., Li N., Li N. Zibara K., Zoltewicz S., Guingab-Cagmat J., et al. Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Sci. Rep. 2016 Apr 14;6:24588. https://doi.org/10.1038/srep24588.

34. Foerch C., Curdt I., Yan B., Dvorak F., Hermans M., Berkefeld J., Raabe A., Neumann-Haefelin T., et al. Serum glial fi brillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry. 2006; 77(2):181–184. https://doi.org/10.1136/jnnp.2005.074823.

35. Undén J., Strandberg K., Malm J., Campbell E., Rosengren L., Stenfl o J., Norrving B., Romner B., et al. Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke diff erentiation. J. Neurol. 2009 Jan;256(1):72–7. https://doi.org/10.1007/s00415–009–0054–8.

36. Foerch C., Niessner M., Back T., Bauerle M., De Marchis G.M., Ferbert A., Grehl H., Hamann G.F., et al. Diagnostic accuracy of plasma glial fi brillary acidic protein for diff erentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin. Chem. 2012 Jan;58(1):237–45. https://doi.org/10.1373/clinchem.2011.172676.

37. Xiong L., Yang Y., Zhang M., Xu W. The use of serum glial fi brillary acidic protein test as a promising tool for intracerebral hemorrhage diagnosis in Chinese patients and prediction of the shortterm functional outcomes. Neurological. Sciences. 2015 Nov; 36(11):2081–7. https://doi.org/10.1007/s10072-015-2317-8.

38. Llombart V., Garcı́a-Berrocoso T., Bustamante A., Giralt D., Rodriguez-Luna D., Muchada M., Penalba A., Boada C., et al. Plasmatic retinol-binding protein 4 and glial fi brillary acidic protein as biomarkers to diff erentiate ischemic stroke and intracerebral hemorrhage. J. Neurochem. 2016;136:416–424. https://doi.org/10.1111/jnc.13419.

39. Indharty S., Japardi I., Fadhli M. Analysis of Glial Fibrillary Acidic Protein (GFAP) serum levels on spontaneous intracerebral hemorrhage non-lesion patients. Bali Med. J. 2016;5(1):49–52. https://doi.org/10.15562/bmj.v5i1.163.

40. Rozanski M., Waldschmidt C., Kunz A., Grittner U., Ebinger M., Wendt M., Winter B., Bollweg K., et al. Glial fi brillary acidic protein for prehospital diagnosis of intracerebral hemorrhage. Cerebrovasc. Dis. 2017;43(1–2):76–81. https://doi.org/10.1159/000453460.

41. Luger S., Witsch J., Dietz A., Hamann G.F., Minnerup J., Schneider H., Sitzer M., Wartenberg K.E., et al. Glial fi brillary acidic protein serum levels distinguish between intracerebral hemorrhage and cerebral ischemia in the early phase of stroke. Clin. Chem. 2017;63(1):377–385. https://doi.org/10.1373/clinchem.2016.263335.

42. Sarfo F.S., Owusu D., Adamu S., Awuah D., Appiah L., Amamoo M., Loglo A., Owolabi M., Ovbiagele B. Plasma Glial Fibrillary Acidic Protein, Copeptin, and Matrix Metalloproteinase-9 Concentrations among West African Stroke Subjects Compared with Stroke-Free Controls. J. Stroke Cerebrovasc. Dis. 2018 Mar;27(3):633–644. https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.035.

43. Aurell A., Rosengren L.E., Karlsson B., Olsson J.E., Zbornikova V., Haglid K.G. Determination of S-100 and glial fi brillary acidic protein concentrations in cerebrospinal fl uid after brain infarction. Stroke. 1991 Oct;22(10):1254–8. https://doi.org/10.1161/01.str.22.10.1254.

44. Hjalmarsson C., Bjerke M., Andersson B., Blennow K., Zetterberg H., Aberg N.D., Olsson B., Eckerström C., et al. Neuronal and glia-related biomarkers in cerebrospinal fl uid of patients with acute ischemic stroke. J. Cent. Nerv. Syst. Dis. 2014 May 19;6:51–8. https://doi.org/10.4137/JCNSD.S13821.

45. Brouns R,. De Vil B., Cras P., De Surgeloose D., Mariën P., De Deyn P.P. Neurobiochemical markers of brain damage in cerebrospinal fl uid of acute ischemic stroke patients. Clin. Chem. 2010 Mar;56(3):451–8. https://doi.org/10.1373/clinchem.2009.134122.

46. Камчатнов П.Р., Рулева Г.Ю., Дукин С.Ф. Содержание нейроспецифических белков и аутоантител к ним в сыворотке крови больных с острым ишемическим инсультом. Журнал неврологии и психиатрии им. C.C. Корсакова. 2009; 5: 69–72.

47. Liu G., Geng J. Glial fi brillary acidic protein as a prognostic marker of acute ischemic stroke. Hum Exp Toxicol. 2018 Oct;37(10):1048–1053. https://doi.org/10.1177/ 0960327117751236.

48. Surjawan Y., As’ad S., Ranakusuma T.A.S., Wijaya A. The different pattern of blood S100b protein and GFAP concentrations in ischemic stroke. Medical Journal of Indonesia. 2013 November; 22(4):215–220. https://doi.org/10.13181/mji.v22i4.602.


Для цитирования:


Топузова М.П., Алексеева Т.М., Панина Е.Б., Вавилова Т.В., Портик О.А., Ковзелев П.Д. ВОЗМОЖНОСТЬ ИСПОЛЬЗОВАНИЯ ГЛИАЛЬНОГО ФИБРИЛЛЯРНОГО КИСЛОГО БЕЛКА КАК БИОМАРКЕРА В ОСТРОМ ПЕРИОДЕ ИНСУЛЬТА. Российский неврологический журнал. 2019;(4):4-15. https://doi.org/10.30629/2658-7947-2019-24-4-4-15

For citation:


Topuzova M.P., Alekseeva T.M., Panina E.B., Vavilova T.V., Portik O.A., Kovzelev P.D. THE POSSIBILITY OF USING GLIAL FIBRILLARY ACIDIC PROTEIN AS A BIOMARKER IN THE ACUTE PERIOD OF STROKE. Russian neurological journal. 2019;(4):4-15. (In Russ.) https://doi.org/10.30629/2658-7947-2019-24-4-4-15

Просмотров: 325


ISSN 2658-7947 (Print)
ISSN 2686-7192 (Online)